Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-621 in healthy volunteers for Herpes Simplex Virus Infection
NCT02346760Phase 1Completed
- Sponsor
- United BioPharma
- Start
- Dec 2015
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UB-621 in herpes simplex virus infection, sponsored by United BioPharma. Primary endpoint: Number of participants with adverse events at 112 days. Started Dec 2015; status: completed.
02
Drugs
UB-621
03
Conditions
herpes simplex virus infection
Beyond the preview
Go deeper on NCT02346760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346760.